<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04131907</url>
  </required_header>
  <id_info>
    <org_study_id>PR1087</org_study_id>
    <nct_id>NCT04131907</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Evaluate the Safety and Efficacy of the Optilume™ BPH Catheter System in Men With Symptomatic BPH</brief_title>
  <acronym>PINNACLE</acronym>
  <official_title>A Prospective, Multicenter, Double Blind, Randomized, Clinical Study to Evaluate the Safety and Efficacy of the Optilume™ BPH Catheter System in Men With Symptomatic BPH</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Urotronic Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ClinLogix. LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Urotronic Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PINNACLE is a prospective, multi-center, randomized control clinical trial to establish the&#xD;
      safety and efficacy of the Optilume™ BPH Catheter System in the treatment of benign prostatic&#xD;
      hyperplasia (BPH)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 5, 2020</start_date>
  <completion_date type="Anticipated">October 2026</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomized study with a non-randomized, Pharmacokinetics arm. Subjects randomized to the Control arm are allowed to crossover to the Test arm if they meet the eligibility criteria after completing the 3-Month Follow-up Visit and prior to the close of the 12-Month visit window.&#xD;
Up to 625 subjects will be enrolled (i.e. consented) in the study in order to identify 162 eligible subjects (147 randomized subjects and 15 Pharmacokinetic subjects)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Subjects in the Randomization arm of the study are randomized in a 2:1 allocation of Test to Control. The treating physician is unblinded to the treatment assignment. A blinded person at the study site conducts all study follow-up visits through the 12-Month follow-up visit (or until the subject is unblinded). The subject may be unblinded prior to the 12-Month visit if it is medically necessary, which includes the subject seeking alternative BPH therapy due to continued or recurrent BPH symptoms.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in International Prostate Symptom Score (IPSS)</measure>
    <time_frame>12 months</time_frame>
    <description>Change in subjects' International Prostate Symptom Score (IPSS) from pre-procedure to 12-months. The IPSS can be interpreted as follows: 0-7 mildly symptomatic, 8-19 moderately symptomatic, and 20-35 severely symptomatic.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major Device Related Serious Complications</measure>
    <time_frame>12 months</time_frame>
    <description>Rate of major device related serious complications</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Optilume™ BPH Catheter System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Optilume™ BPH, Prostatic Dilation DCB Catheter is a dilation catheter used to exert radial force to dilate the prostatic urethra resulting in a commissurotomy. The distal end of the catheter has a semi-compliant inflatable double lobe balloon that is coated with a proprietary coating containing the active pharmaceutical paclitaxel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Device</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The Sham Device is a 21 Fr Optilume BPH, Prostatic Pre-dilation Catheter within the sheath.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pharmacokinetics Optilume Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single arm of 15 non-randomized subjects will be treated in the pharmacokinetics (PK) arm. These subjects will be treated with the Optilume BPH Catheter System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Optilume BPH Catheter System</intervention_name>
    <description>The Optilume™ BPH, Prostatic Dilation DCB Catheter is a dilation catheter used to exert radial force to dilate the prostatic urethra resulting in a commissurotomy. The distal end of the catheter has a semi-compliant inflatable double lobe balloon that is coated with a proprietary coating containing the active pharmaceutical paclitaxel.</description>
    <arm_group_label>Optilume™ BPH Catheter System</arm_group_label>
    <arm_group_label>Pharmacokinetics Optilume Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Optilume Sham Device</intervention_name>
    <description>21 Fr sheathed Optilume™ BPH Prostatic Pre-dilation Catheter (modified to prevent inflation)</description>
    <arm_group_label>Sham Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male subject 50-80 years of age who has symptomatic BPH&#xD;
&#xD;
          2. International Prostate Symptom Score (IPSS) ≥ 13&#xD;
&#xD;
          3. Peak urinary flow rate (Qmax) ≥ 5 ml/sec and ≤ 12 ml/sec (with minimum voided volume&#xD;
             of ≥ 150 ml)&#xD;
&#xD;
          4. Prostate volume 20 to 80 gm as determined by transrectal ultrasound (TRUS)&#xD;
&#xD;
          5. Prostatic urethral length ≥ 32 mm and ≤ 55 mm as determined by TRUS&#xD;
&#xD;
          6. History of inadequate response, contraindication, or refusal of BPH medical therapy&#xD;
&#xD;
          7. Able to complete the study protocol in the opinion of the investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unable or unwilling to sign the Informed Consent Form (ICF) and/or comply with all the&#xD;
             follow-up requirements&#xD;
&#xD;
          2. Unwilling to abstain or use protected sex for the first 30 days post treatment&#xD;
&#xD;
          3. Unwilling to abstain from sexual intercourse or use a highly effective contraceptive&#xD;
             for at least 6 months post-procedure&#xD;
&#xD;
          4. Presence of an artificial urinary sphincter or stent(s) in the urethra or prostate&#xD;
&#xD;
          5. Any prior minimally invasive intervention (e.g. TUNA, Balloon, Microwave, Rezūm,&#xD;
             UroLift) or surgical intervention of the prostate&#xD;
&#xD;
          6. Prostate specific antigen (PSA) ≥ 10 ng/ml unless prostate cancer is ruled out by&#xD;
             biopsy&#xD;
&#xD;
          7. Confirmed or suspected malignancy of prostate or bladder&#xD;
&#xD;
          8. Active or history of epididymitis within the past 3 months&#xD;
&#xD;
          9. Previous pelvic irradiation or pelvic trauma surgery&#xD;
&#xD;
         10. Active urinary tract infection (UTI) confirmed by culture&#xD;
&#xD;
         11. Bacterial prostatitis within the last 12 months&#xD;
&#xD;
         12. Non-bacterial prostatitis within the last 5 years&#xD;
&#xD;
         13. Visible or invisible hematuria (&gt; 4 Red Blood Cells (RBCs) per high power field) on 2&#xD;
             separate urine specimens within the last 3 months without a know contributing factor&#xD;
&#xD;
         14. Neurogenic bladder or sphincter abnormalities or neurological disorders that might&#xD;
             affect bladder or sphincter function&#xD;
&#xD;
         15. History of urinary incontinence&#xD;
&#xD;
         16. Previous or current diagnosis of urethral strictures, bladder neck contracture or&#xD;
             detrusor muscle spasms&#xD;
&#xD;
         17. Previous rectal surgery, other than hemorrhoidectomy&#xD;
&#xD;
         18. Use of antihistamines, anticonvulsants or antispasmodics within 1 week prior to&#xD;
             baseline assessment unless there is documented evidence of stable dosing for at least&#xD;
             6 months&#xD;
&#xD;
         19. Use of antidepressants with adrenergic effects (i.e. duloxetine, imipramine and&#xD;
             amitriptyline), long-acting anticholinergics (LAAC) for chronic obstructive pulmonary&#xD;
             disease (COPD), or androgens within 2 weeks prior to baseline assessment unless there&#xD;
             is documented evidence of stable dosing for at least 3 months prior to baseline&#xD;
             assessment&#xD;
&#xD;
         20. Use of Luteinizing Hormone-Releasing Hormone (LHRH) analogs within 12 months prior to&#xD;
             baseline assessment&#xD;
&#xD;
         21. Use of Type II 5-alpha reductase inhibitor [e.g. finasteride (Proscar, Propecia)]&#xD;
             within 3 months of baseline assessment&#xD;
&#xD;
         22. Use of 5-alpha reductase inhibitor [e.g. dutasteride (Avodart)] within 6 months of&#xD;
             baseline assessment&#xD;
&#xD;
         23. Use of estrogen or drugs producing androgen suppression unless there is documented&#xD;
             evidence of stable dosing for at least 3 months prior to baseline assessment&#xD;
&#xD;
         24. Use of alpha blockers or daily dose PDE5 inhibitor (e.g. Cialis) within 2 weeks of&#xD;
             baseline assessment&#xD;
&#xD;
         25. Use of warfarin or novel oral anti-coagulants [e.g., apixaban (Eliquis), fondaparinux&#xD;
             (Arixtra), rivaroxaban (Xarelto) or edoxaban (Savaysa)], unless the medication is&#xD;
             safely discontinued prior to the procedure and is not planned to be restarted for at&#xD;
             least 5 days post-procedure&#xD;
&#xD;
         26. Use of anti-platelet medications (e.g., clopidogrel, aspirin) within 10 days prior to&#xD;
             the procedure or planned use within 5 days post-procedure&#xD;
&#xD;
         27. History of hypersensitivity reactions to paclitaxel, on medication that may have&#xD;
             negative interaction with paclitaxel, presence of solid tumor with a baseline&#xD;
             neutrophil count of &lt;1500 cells/mm3 or AIDS-related Kaposi's sarcoma with baseline&#xD;
             neutrophil count of &lt;1000 cells/mm3&#xD;
&#xD;
         28. Incidence of spontaneous urinary retention within 6 months prior to baseline&#xD;
             assessment&#xD;
&#xD;
         29. Current post-void residual volume &gt; 300 ml or catheter dependent bladder drainage&#xD;
&#xD;
         30. Known poor detrusor muscle function (e.g. Qmax &lt; 5 ml/sec)&#xD;
&#xD;
         31. Current bladder or prostatic urethral stones&#xD;
&#xD;
         32. Biopsy of prostate within 40 days prior to procedure&#xD;
&#xD;
         33. History of cancer in non-genitourinary system which is not considered in complete&#xD;
             remission (except basal cell or squamous cell carcinoma of the skin). A potential&#xD;
             participant is considered in complete remission if there has been no evidence of&#xD;
             cancer within five years&#xD;
&#xD;
         34. Current uncontrolled diabetes (i.e. hemoglobin A1c ≥ 8%)&#xD;
&#xD;
         35. History of clinically significant comorbidities or presence of unstable conditions&#xD;
             [e.g. cardiovascular, lung, renal (serum creatinine &gt; 2.0 mg/dl), hepatic, bleeding&#xD;
             disorders or metabolic impairment] that may confound the results of the study or have&#xD;
             a risk to subject per investigator's opinion&#xD;
&#xD;
         36. Any cognitive disorder that interferes with or precludes direct and accurate&#xD;
             communication with the study investigator regarding the study or affects the ability&#xD;
             to complete the study quality of life questionnaires&#xD;
&#xD;
         37. Life expectancy &lt; 10 years&#xD;
&#xD;
         38. Anatomy (e.g. presence of false passage or size of meatus) is not suitable for&#xD;
             treatment in this study&#xD;
&#xD;
         39. Significant median lobe component [e.g. intravesical prostatic protrusion (IPP) &gt; 1&#xD;
             cm]&#xD;
&#xD;
         40. Device that corresponds with the subject's prostate size is not available&#xD;
&#xD;
         41. Currently enrolled in or plan to enroll in another investigational clinical study for&#xD;
             any disease except for observational only study&#xD;
&#xD;
         42. In the opinion of the investigator, it is not in the subject's best interest to&#xD;
             participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven A Kaplan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mount Sinai Health System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jill Moland</last_name>
    <phone>833-400-4032</phone>
    <email>molandj@urotronic.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Polly Sizemore</last_name>
    <phone>215-855-9054</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Urological Associates of Southern Arizona, PC</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85741</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Arkansas Urology</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Colorado Clinical Research</name>
      <address>
        <city>Golden</city>
        <state>Colorado</state>
        <zip>80401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advanced Urology Institute</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida Urology Partners</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Comprehensive Urologic Care</name>
      <address>
        <city>Lake Barrington</city>
        <state>Illinois</state>
        <zip>60010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regional Urology, LLC</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chesapeake Urology Research Associates</name>
      <address>
        <city>Hanover</city>
        <state>Maryland</state>
        <zip>21076</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chesapeake Urology Research Associates</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Sheldon Freedman MD, Ltd</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>New Jersey Urology</name>
      <address>
        <city>Englewood</city>
        <state>New Jersey</state>
        <zip>07631</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Western New York Urology Associates</name>
      <address>
        <city>Cheektowaga</city>
        <state>New York</state>
        <zip>14225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>AccuMed Research Associates</name>
      <address>
        <city>Garden City</city>
        <state>New York</state>
        <zip>11530</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Manhattan Medical Research Practice, PLLC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Associated Urologists of NC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Carolina Urologic Research Center</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Urology Austin, PLLC</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>North Austin Urology</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78750</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rio Grande Urology</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clear Lake Specialties</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Urology Associates</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Montreal Hospital Center (CHUM)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 3E4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 16, 2019</study_first_submitted>
  <study_first_submitted_qc>October 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2019</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BPH, Drug Coated Balloon, DCB, prostate, LUTS, Optilume</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

